The Avicena Group, Inc (the “Company”) selected CRT Capital Group LLC (“CRT”) to act as its financial advisor in connection with reviewing the Company’s strategic and capital market alternatives, including exploration of financing, any merger or acquisition, joint venture, divestiture, spin-off, or other strategic or capital market transaction (each, a “Transaction”) that the Company chose to pursue.
About The Avicena Group, Inc
Avicena Group, Inc., a biotechnology company, develops central nervous system therapeutics for neurodegenerative diseases. The company’s technologies have applications in pharmaceuticals and dermaceuticals. Its pharmaceutical program focuses on neurological disorders (orphan diseases). The company provides various products under pipeline that have applications in the area of neurodegenerative and neuro-muscluar diseases, such as ALS (Lou Gehrig’s disease), Huntington’s disease, Parkinson’s disease, Duchenne muscular dystrophy, and Charcot-Marie-tooth syndrome. It also offers Nurigene, a skin care products line; and dermaceutical ingredient blends and nutraceuticals.
About M.M. Dillon & Co.
M.M. Dillon & Co. (formerly CRT Investment Banking LLC) is an employee owned partnership where industry and product specialists collaborate closely to provide creative, idea-driven advice and solutions to its institutional and corporate clients. M.M. Dillon offers public and private financing, M&A advisory and restructuring advisory services. M.M. Dillon’s team of experienced professionals provides execution capabilities for companies across a range of industry sectors. The firm’s senior banking professionals have a minimum of 20 years of experience with major Wall Street firms.